Dapansutrile not checked
Olatec Therapeutics, Inc. · OLT1177 capsules · OLT1177
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.”In the company’s words, NCT05658575 on ClinicalTrials.gov
- Tested for
- Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
- Main trialPhase 2/3
- “The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.”In the company’s words, NCT05658575 on ClinicalTrials.gov
- Other names
- OLT1177 capsules · OLT1177
Other drugs for Acute Gout Flare
Coming up1
- 31 DecPhase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 31 Dec 2026 | Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | |
| Phase 2Terminated | 29 May 2018 | Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome | |
| Phase 2Terminated | 28 Jul 2022 | Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome | |
| Phase 2Authorised | not given | A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with Type 2 Diabetes Mellitus Dapan-Dia Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026